Business Context and Reporting Period
This Form 8-K filing by VistaGen Therapeutics, Inc. is dated September 19, 2011. The report discloses a material change in the company's principal officers, specifically the appointment of a new Acting Chief Financial Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and compensation terms rather than financial performance.
Material Changes
On September 19, 2011, Jerrold D. Dotson, CPA, was appointed as the Company's Acting Chief Financial Officer (Principal Financial and Accounting Officer). Key terms of his appointment include:
- Time Commitment: Minimum of three business days per week exclusively for the Company.
- Cash Compensation: $9,500 per month.
- Equity Compensation: Options to purchase 50,000 shares of common stock at an exercise price of $2.55 per share.
- Vesting Schedule: 3,125 shares vest on December 19, 2011; the remainder vests in equal monthly installments over 45 months, with 100% vesting by September 19, 2015.
- Plan Governance: Terms are subject to the Company's 2008 Stock Incentive Plan.
Mr. Dotson previously served as Corporate Controller for Discovery Foods (2009–2011) and held various finance roles at Calypte Biomedical Corporation (2000–2008). As of the report date, he owned no shares of the Company.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on future strategy, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the definitive terms of the stock options under the 2008 Stock Incentive Plan.
- Confirm the total number of shares available for issuance under the existing stock incentive plan to assess dilution impact.
- Review the Company's recent financial statements to understand the cash flow implications of the new monthly compensation obligation.
- Check for any prior filings regarding the departure of the previous Chief Financial Officer.